Funding: The research presented in this paper was funded by OPTINOSE, Inc.
View and Perspective
Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment
Article first published online: 28 JUN 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 53, Issue 8, pages 1341–1349, September 2013
How to Cite
Tepper, S. J. (2013), Clinical Implications for Breath-Powered Powder Sumatriptan Intranasal Treatment. Headache: The Journal of Head and Face Pain, 53: 1341–1349. doi: 10.1111/head.12166
Conflict of Interest:Dr. Tepper receives grants/research support from Allergan, ATI, BristolMyerSquibb, GSK, Merck, NuPathe, OPTINOSE, and Zogenix. These grants do not go to him personally, and do not count toward his salary at Cleveland Clinic.
All amounts received are <$10,000/year per Cleveland Clinic Policy and are listed on the Cleveland Clinic website.
In the last 12 months, he has served as a consultant for Allergan, ATI, MAP, Nautilus, NuPathe, Pfizer, and Zogenix.
In the last 12 months, he has served on the speakers bureau for Allergan, MAP, Nautilus, and Zogenix.
In the last 12 months, he served on advisory boards for Allergan, ATI, MAP, Nautilus, NuPathe, USWorldMeds, and Zogenix.
Dr. Tepper holds stock options in ATI.
- Issue published online: 10 SEP 2013
- Article first published online: 28 JUN 2013
- Manuscript Accepted: 29 APR 2013
- OPTINOSE, Inc
Options for accessing this content:
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!